Ana C. Garrido-Castro

Oct 9, 2024 | nature.com | Naiara Perurena |Yoona Yang |Carrie Rodriguez |Alycia Gardner |Patrick Loi |Yilin Xu | +9 more

AbstractTriple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and has the highest rate of recurrence1. The predominant standard of care for advanced TNBC is systemic chemotherapy with or without immunotherapy; however, responses are typically short lived1,2. Thus, there is an urgent need to develop more effective treatments. Components of the PI3K pathway represent plausible therapeutic targets; more than 70% of TNBCs have alterations in PIK3CA, AKT1 or PTEN3,4,5,6.

Jul 16, 2024 | ascopubs.org | Rebecca A. Shatsky |Ana C. Garrido-Castro |William Gradishar

NAT for EBC provides multiple advantages. Historically, NAT was only given for inoperable or locally advanced BC with the goal of downstaging tumors in the breast and axilla to render them operable and/or more likely to achieve breast conservation.

Apr 3, 2024 | nature.com | Paolo Tarantino |Ana C. Garrido-Castro |Filipa Lynce |Sara M. Tolaney

AbstractTo evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors (p = 0.001 and p < 0.001, respectively).

Dec 14, 2023 | nature.com | Paolo Tarantino |Ana C. Garrido-Castro |Brittany L. Bychkovsky |Lynette M. Sholl |Matthew Meyerson |Rinath Jeselsohn | +5 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-023-43324-w, published online 18 November 2023In this article, the author names Paolo Tarantino, Hersh Gupta, Melissa E. Hughes, Janet Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Li, Ana C. Garrido-Castro, Romualdo Barroso-Sousa, Brittany L. Bychkovsky, Simona DiLascio, Lynette Sholl, Laura MacConaill, Neal Lindeman, Bruce E. Johnson, Matthew Meyerson, Rinath Jeselsohn, Xintao Qiu, Rong Li, Henry Long, Eric P.

Jun 2, 2023 | nature.com | Ana C. Garrido-Castro |Faina Nakhlis |Laura Warren |Beth Harrison |Sara M. Tolaney |Beth Overmoyer

AbstractInflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer that presents as de novo metastatic disease in 20–30% of cases, with one-third of cases demonstrating HER2-positivity. There has been limited investigation into locoregional therapy utilization following HER2-directed systemic therapy for these patients, and their locoregional progression or recurrence (LRPR) and survival outcomes.